Ki‐67 expression in breast carcinoma

The number of mitoses and, thus, the proliferative capacity of a tumor is one of the most crucial variables for tumor grading. The Ki‐67 nuclear antigen may be considered as an alternative to mitotic counts in grading schemes and as a single parameter that can be used in fine‐needle aspirates and small biopsies.

[1]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[2]  S. Pinder,et al.  The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy , 1998, Cancer.

[3]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Ellis,et al.  Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Powles.  Adjuvant therapy for early breast cancer: a time to refine. , 1997, Journal of the National Cancer Institute.

[6]  Umberto Veronesi,et al.  Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes , 1997, The Lancet.

[7]  C. Osborne,et al.  Cytological evaluation of biological prognostic markers from primary breast carcinomas , 1997, Breast Cancer Research and Treatment.

[8]  R. Gelber,et al.  Prognostic importance of thymidylate synthase expression in early breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Torhorst,et al.  MIB-1 (Ki-67) immunostaining of breast cancer cells in cytologic smears. , 1997, Acta cytologica.

[10]  M. Reiss,et al.  Reappraisal of the role of axillary lymph node dissection in the conservative treatment of breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. R. Shetty.  The new era in breast cancer. , 1996, Archives of surgery.

[12]  J. G. Schuler,et al.  The new era in breast cancer. Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. , 1996, Archives of surgery.

[13]  T. Powles,et al.  Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M J Gaffey,et al.  Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. , 1995, American journal of clinical pathology.

[15]  I. Ellis,et al.  Histologic grading of breast cancer. Let's do it. , 1995, American journal of clinical pathology.

[16]  J. Forbes,et al.  Present and future projects of the international breast cancer study group , 1994, Cancer.

[17]  P. Lampertico,et al.  Proliferation index as a prognostic marker in breast cancer , 1993, Cancer.

[18]  P. Hall,et al.  The relevance of antibody concentration to the immunohistological quantification of cell proliferation‐associated antigens , 1993, Histopathology.

[19]  Johannes Gerdes,et al.  Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections , 1992, The Journal of pathology.

[20]  G. Serio,et al.  p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. , 1992, American journal of clinical pathology.

[21]  B. Gusterson,et al.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Blamey,et al.  Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long‐term follow‐up , 1992, Histopathology.

[23]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[24]  D. Lane,et al.  A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction , 1991, The Journal of pathology.

[25]  G. Hortobagyi,et al.  Ki‐67 immunostaining in node‐negative stage I/II breast carcinoma. Significant correlation with prognosis , 1991, Cancer.

[26]  D. Campani,et al.  Estrogen, Progesterone Receptors and Proliferating Activity Evaluated by Immunocytochemistry in Breast Cancer , 1991, The International journal of biological markers.

[27]  D. Stefano,et al.  A comparative study of histopathology, hormone receptors, peanut lectin binding, ki‐67 immunostaining, and nucleolar organizer region‐associated proteins in human breast cancer , 1991, Cancer.

[28]  A E Dawson,et al.  Comparative assessment of proliferation and DNA content in breast carcinoma by image analysis and flow cytometry. , 1990, The American journal of pathology.

[29]  P. Hall,et al.  Review: assessment of cell proliferation in histological material. , 1990, Journal of clinical pathology.

[30]  O. Kallioniemi,et al.  Evaluation of cell proliferation in breast carcinoma. Comparison of Ki‐67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count , 1990, Cancer.

[31]  P. Isaacson,et al.  Immunoproliferative small-intestinal disease. An immunohistochemical study. , 1989, The American journal of surgical pathology.

[32]  S Friedman,et al.  Prognostic value of histologic grade nuclear components of Scarff‐Bloom‐Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas , 1989, Cancer.

[33]  P. Galand,et al.  Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labelling for marking S phase cells in paraffin sections from animal and human tissues , 1989, Cell and tissue kinetics.

[34]  I. Ellis,et al.  Ki67 immunostaining in primary breast cancer: pathological and clinical associations. , 1989, British Journal of Cancer.

[35]  K. Sasaki,et al.  Relationship between labeling indices of KI‐67 and brdurd in human malignant tumors , 1988, Cancer.

[36]  R. Camplejohn,et al.  Comparison of monoclonal antibody Ki-67 reactivity with grade and DNA flow cytometry of breast carcinomas. , 1988, British Journal of Cancer.

[37]  S Friedman,et al.  The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M Bibbo,et al.  Quantitation of estrogen receptor content and Ki-67 staining in breast carcinoma by the microTICAS image analysis system. , 1987, Analytical and quantitative cytology and histology.

[39]  R. Gelber,et al.  Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis , 1986, Cancer.

[40]  P. Quirke,et al.  Flow cytometry: Methodology and applications in pathology , 1986, The Journal of pathology.

[41]  A. Goldhirsch,et al.  Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. , 1985, Human pathology.

[42]  C. Elston,et al.  The assessment of histological differentiation in breast cancer. , 1985, The Australian and New Zealand journal of surgery.

[43]  H Stein,et al.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.

[44]  P. Dean,et al.  Cell‐Cycle Analysis Using A Monoclonal Antibody to Brdurd , 1984, Cell and tissue kinetics.

[45]  Johannes Gerdes,et al.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.

[46]  M. Black,et al.  Prognosis in breast cancer utilizing histologic characteristics of the primary tumor , 1975 .

[47]  M. Tubiana,et al.  The relationship between growth rate, labelling index and histological type of human solid tumours. , 1973, European journal of cancer.

[48]  Jacob Cohen,et al.  Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit. , 1968 .

[49]  Yasargil Ec.  HOMOGRAFT REPLACEMENT OF THE AORTIC VALVE. , 1964, Lancet.

[50]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[51]  H. Bloom,et al.  Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.

[52]  H. Bloom.  Further Studies on Prognosis of Breast Carcinoma , 1950, British Journal of Cancer.

[53]  H. Bloom.  Prognosis in Carcinoma of the Breast , 1950, British Journal of Cancer.

[54]  R. W. Scarff,et al.  THE POSITION OF HISTOLOGY IN THE PROGNOSIS OF CARCINOMA OF THE BREAST. , 1928 .

[55]  Robert B. Greenough,et al.  Varying Degrees of Malignancy in Cancer of the Breast , 1925 .

[56]  K. Pearson.  On the Criterion that a Given System of Deviations from the Probable in the Case of a Correlated System of Variables is Such that it Can be Reasonably Supposed to have Arisen from Random Sampling , 1900 .

[57]  D. Hansemann.  Ueber die Anaplasie der Geschwulstzellen und die asymmetrische Mitose , 1892, Archiv für pathologische Anatomie und Physiologie und für klinische Medicin.

[58]  D. Hansemann.  Ueber asymmetrische Zelltheilung in Epithelkrebsen und deren biologische Bedeutung , 1890, Archiv für pathologische Anatomie und Physiologie und für klinische Medicin.

[59]  B. Gusterson.  Prognostic variables and future predictors of behaviour and response. , 1996, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[60]  J. Seidman,et al.  Relationship of the size of the invasive component of the primary breast carcinoma to axillary lymph node metastasis , 1995, Cancer.

[61]  I. Ellis,et al.  Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. , 1993, European journal of cancer.

[62]  M. Loda,et al.  DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma. , 1992, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[63]  W. Simon,et al.  Growth fraction in breast carcinoma determined by Ki-67 immunostaining: correlation with pathological and clinical variables. , 1992, Gynecologic and obstetric investigation.

[64]  N. Wright,et al.  Assessment of Cell Proliferation in Clinical Practice , 1992, Springer Japan.

[65]  S. Veronese,et al.  Detection of Ki-67 proliferation rate in breast cancer. Correlation with clinical and pathologic features. , 1991, American journal of clinical pathology.

[66]  M. Zelen,et al.  Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. , 1989, The New England journal of medicine.

[67]  A. Chott,et al.  Ki-67 immunoreactivity in breast carcinomas in relation to transferrin receptor expression, estrogen receptor status and morphological criteria. An immunohistochemical study. , 1989, Oncology.

[68]  P. Betta,et al.  Correlation of proliferative activity with pathological features in breast carcinoma. , 1989, European journal of gynaecological oncology.

[69]  A. Chott,et al.  K-67 Immunoreactivity in Breast Carcinomas in Relation to Transferrin Receptor Expression, Estrogen Receptor Status and Morphological Criteria , 1989 .

[70]  Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. , 1988, The New England journal of medicine.

[71]  C. Redmond,et al.  Histologic grading of breast cancer. , 1980, Pathology annual.

[72]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .